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Visual processing speedSpeed of processing is a particularly important characteristic of the visual system. Often a behavioral
reaction to a visual stimulus must be faster than the conscious perception of that stimulus, as is the case
with many sports (e.g., baseball). Visual psychophysics provides a relatively simple and precise means of
measuring visual processing speed called the temporal contrast sensitivity function (tCSF). Past study has
shown that macular pigment (a collection of xanthophylls, lutein (L), meso-zeaxanthin (MZ) and zeaxan-
thin (Z), found in the retina) optical density (MPOD) is positively correlated with the tCSF. In this study,
we found similar correlations when testing 102 young healthy subjects. As a follow-up, we randomized
69 subjects to receive a placebo (n = 15) or one of two L and Z supplements (n = 54). MPOD and tCSF were
measured psychophysically at baseline and 4 months. Neither MPOD nor tCSF changed for the placebo
condition, but both improved signiﬁcantly as a result of supplementation. These results show that an
intervention with L and Z can increase processing speed even in young healthy subjects.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
One likely manifestation of biological thrift is that a single,
typically widely available, molecule can often play many and
diverse roles throughout nature. Lutein (L)1 and zeaxanthin (Z),
for instance, play a critical role in plant photosynthesis [4] and
the embryonic development of chicks (giving the yellow to egg
yolk; [18]). L and Z are antiatherogenic [6] but also help prevent
photo-oxidative degradation of the skin [24]. L and Z are potent
lipid-based antioxidants and anti-inﬂammatories [31] but also
serve as optical ﬁlters within the macula of the eye [13]. They
are ornamental [10] and yet found within human brain information
processing areas such as the hippocampus [30]. Their diversity
throughout nature is reﬂected by an equally impressive diversity
within our biology.
The behavioral effects associated with L and Z seem no less
encompassing. Signiﬁcant relations have been reported betweenmacular pigment optical density (MPOD; L and Z and meso-Z
measured in the retina) and a large number of visual measures
including glare disability and discomfort, photostress recovery,
and chromatic contrast [13]. Measures of L and Z within the ret-
ina appear to be strongly linked to measures of L and Z in brain
tissue [29] and MPOD has also been linked to measures that are
mediated by brain such as cognition [15,9,23], auditory thresh-
olds [33], balance time, reaction time [22], and temporal vision
[11,21,2].
Taken together, L and Z seem important to biology, in general,
and humans are no exception. In many cases, the basis for their
functional effects has been well characterized. For example, in
the eye, many effects are due simply to selective ﬁltering. How
(and really if) they inﬂuence brain function, however, is less clear.
One possibility is simply protection from the accumulated effects
of oxidative and inﬂammatory stress. Data linking reduced MPOD
to dementia [19] and cognitive impairment [23] is consistent with
that possibility. Another possibility, more relevant to younger indi-
viduals and palliative approaches, is a direct improvement by some
type of local interaction with neural cells (the so-called neural efﬁ-
ciency hypothesis; [11,36,21]). Such interactions (as opposed to
simply enhanced protection) would imply that supplementation
over a relatively short time period (yet long enough to increase
Fig. 1. The average baseline tCSF values for subjects in the placebo (Xs) and
treatment conditions (squares). The shape of the template curve depicted by the
solid line was derived from Wooten et al. [35]. The similarity in shape suggests our
temporal measures were a valid estimate of the general temporal contrast
sensitivity function.
Table 1
Baseline correlations between macular pigment and measures of temporal vision and
temporal contrast sensitivity (N = 102).
Macular pigment (300 eccentricity)
r-Value p-Value (one tailed)
Foveal temporal contrast sensitivity
1.4 log hertz 0.29 <0.005
1.0 log hertz 0.27 <0.005
0.4 log hertz 0.26 <0.005
Parafoveal temporal contrast sensitivity
1.4 log hertz 0.21 <0.025
1.0 log hertz 0.26 <0.005
0.4 log hertz 0.26 <0.005
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ments in tasks that are generally mediated by the central nervous
system.2 To test this idea, we measured MPOD and temporal vision
(speciﬁcally, the temporal contrast sensitivity function, tCSF) in a
group of young healthy subjects.
We chose the tCSF because the stimuli can be designed to obvi-
ate individual differences mediated by optical effects (e.g., inﬂu-
ence of light absorption by retinal L and Z is eliminated by using
wavelengths not absorbed by MP) and because the retina is known
to follow temporally varying stimuli much faster than brain, hence,
high-frequency thresholds are determined by the rate limiter
which, in this case, appears to be visual cortex [32]. An example
of the tCSF, with the speciﬁc points we assessed, is shown in
Fig. 1. Renzi and Hammond [21] originally found that MPOD was
correlated with tCSF. In the ﬁrst phase of our study, we correlated
tCSF with MPOD in 102 subjects. In the second phase, we utilized a
placebo-controlled design and randomized subjects to receive
either placebo (n = 15) or a xanthophyll-containing supplement
(n = 54).Method
Subjects
Young adults (ages 18–32 years) were recruited the University
of Georgia and Athens, GA community for a four-month double-
blind supplementation trial. At the time of enrollment, subjects
were randomly assigned (simple randomizing without replace-
ment) to one of three treatment groups. The treatment groups were
either 20 mg Z/day (N = 29; EyePromise Zeaxanthin, ZeaVision, LLC;
Chesterﬁeld, MO) or a ‘‘multi’’ condition 26 mg Z + 8 mg L + 190 mg
mixed n-s fatty acids/day (N = 25; EyePromise vizual EDGE, ZeaVi-
sion, LLC; Chesterﬁeld, MO). A total of 15 subjects received a pla-
cebo. Supplements were provided to subjects in an unmarked
bottle, and theywere instructed to follow dosage instructions listed
under the cap for each day when taken with a meal.
All methods and procedures were approved by the University of
Georgia’s Institutional Review Board and adhered to the principles
in the Declaration of Helsinki. Subjects provided written consent.2 Although a purely protective effect cannot be ruled out. Even young subjects can
often have quite high levels of inﬂammatory and oxidative stress [5] and functiona
improvements would likely result from their amelioration.lMPOD and temporal visual function were measured on two sepa-
rate occasions during a single week in order to determine a stable
baseline value (we then used the average for the baseline correla-
tions shown in Table 1). At the second visit, subjects received the
masked pill bottles and were instructed to take the contents with
a meal and to refrain from making substantial changes to their diet
during the intervention. Compliance was assessed by questioning
the subjects twice during and once at the conclusion of the
intervention.
Assessment of macular pigment
Macular pigment optical density (MPOD) was determined at
30-min retinal eccentricity using customized heterochromatic
ﬂicker photometry with a table-top device described by [34]. In
brief, a 460 nm light-emitting diode (LED) is presented in square-
wave alternation with a 570 nm LED creating the perception of
ﬂicker, which is presented at an individually-customized rate.
The difference in energy of the 460 nm LED required to eliminate
ﬂicker in the fovea (where macular pigment accumulates) com-
pared to the parafovea (an area of the retinal without macular pig-
ment) was used to derive MPOD.
Assessment of temporal contrast sensitivity
Temporal contrast sensitivity was assessed by the customized,
LED-driven tabletop device described by Wooten et al. [35]. The
test stimulus consisted of a 1-degree 660 nm target at the center
of a 5.5-degrees 660 nm surround, separated by a 4 arc minute
gap. A ﬁxation point at the center of the target was used for foveal
measurements. Unlike MP density, which was only measured in
the central 1-degree, we also assessed parafoveal temporal sensi-
tivity. To obtain these measures, subjects ﬁxated a small red point
placed at 7-degrees in the nasal visual ﬁeld. Subjects viewed the
stimuli through a 3 mm artiﬁcial pupil. Measurements of temporal
contrast sensitivity occurred at 0.4, 1.0, and 1.4 log frequency (i.e.,
the LEDs were presented in sine-wave at 2.51, 10, and 25 Hz,
respectively). Temporal contrast sensitivity values were derived
from temporal contrast thresholds, or the depth of modulation at
which the target ﬁrst appeared to ﬂicker. Depth of modulation
refers to the amplitude modulation of the sine wave, or the differ-
ence between the maximum and minimum luminance of the wave.
For each frequency setting, the target was initially set at 0% depth
of modulation (and therefore perceptually fused) and increased
until the subject reported ﬂicker detection, for a total of ﬁve
ascending trials for each frequency setting.
Statistical analyses
Results were analyzed with SPSS 17.0. The baseline relations
were assessed using a Pearson product moment correlational
Table 2
Macular pigment at baseline and after 4 months of supplementation for each group.
Group N Baseline Final Change t-Value p-Value
Placebo 15 0.37 ± 0.15 0.35 ± 0.16 0.02 1.28 0.22
Zeaxanthin 29 0.40 ± 0.15 0.49 ± 0.16 +0.09 4.442 <0.01
Multi 25 0.33 ± 0.15 0.42 ± 0.16 +0.09 4.672 <0.01
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sitivity after supplementation were assessed with paired samples
t-tests with signiﬁcance also set at p < 0.05. Bonferroni corrections
for multiple t-tests were made based on condition and treatment
group.
Results
As shown in Table 1, and similar to past studies, we found
strong statistical relationships between MPOD and tCSF across
the three frequencies that we tested. These strong relations were
found both in the fovea, where MP is dense, and the parafovea. This
initial relation motivated the second phase of the study which was
designed to assess whether increasing MPOD could actually result
in a change in temporal processing. Sixty-nine subjects were ran-
domly assigned to receive either placebo or a pure zeaxanthin sup-
plement or xanthophyll-containing multi for 4 months. As shown
in Table 2, MPOD did not change in the placebo group but didTable 3
Changes in measures of foveal and parafoveal temporal contrast sensitivity for subjects ei
Temporal frequency Group Baseline
Foveal 1.4 log hertz Treatment 0.17 ± 0.15
Placebo 0.32 ± 0.18
Foveal 1.0 log hertz Treatment 1.24 ± 0.13
Placebo 1.34 ± 0.14
Foveal 0.4 log hertz Treatment 1.18 ± 0.15
Placebo 1.25 ± 0.16
Parafoveal 1.4 log hertz Treatment 0.39 ± 0.16
Placebo 0.40 ± 0.23
Parafoveal 1.0 log hertz Treatment 1.10 ± 0.13
Placebo 1.14 ± 0.15
Parafoveal 0.4 log hertz Treatment 0.99 ± 0.14
Placebo 1.06 ± 0.16
a p-Values reﬂect Bonferroni correction for multiple comparisons.
Table 4
Changes in measures of foveal and parafoveal temporal contrast sensitivity for subjects in
Temporal frequency Groupa Baseline
Foveal 1.4 log hertz Zeaxanthin 0.18 ± 0.19
Multi 0.17 ± 0.10
Foveal 1.0 log hertz Zeaxanthin 1.25 ± 0.17
Multi 1.24 ± 0.07
Foveal 0.4 log hertz Zeaxanthin 1.19 ± 0.19
Multi 1.17 ± 0.07
Parafoveal 1.4 log hertz Zeaxanthin 0.40 ± 0.19
Multi 0.38 ± 0.12
Parafoveal 1.0 log hertz Zeaxanthin 1.08 ± 0.16
Multi 1.12 ± 0.06
Parafoveal 0.4 log hertz Zeaxanthin 0.99 ± 0.15
Multi 0.99 ± 0.15
a Zeaxanthin Group, N = 28; Multi Group, N = 25.
b p-Values reﬂect Bonferroni correction for multiple comparisons.increase signiﬁcantly in both supplement conditions. In general,
both conditions increased MPOD by nearly 0.10 log units.
The increase in MPOD translated to a concomitant increase in
temporal processing speed for the supplemented subjects. These
data are shown in aggregated form to increase statistical power
(see Table 3). As shown in the table, foveal tCSF values did not
change for the placebos but improved signiﬁcantly in the treat-
ment group. A similar ﬁnding was found for the parafoveal
assessments: no statistically signiﬁcant change for the placebos
but signiﬁcant increases for the treatment group (see Table 3).
Signiﬁcant changes were maintained when analyses were
performed for each treatment condition considered separately
(see Table 4).Discussion
In this study we found that MPOD was positively correlated
with temporal processing speed even when young healthy subjects
were targeted. This latter point is signiﬁcant since young healthy
subjects are typically considered to be at peak efﬁciency and might
be expected to be most resistant to change due to ceiling effects.
Nonetheless, both MPOD and tCSF increased by about 0.10 log
units. This magnitude of change translates to about a 20% increase
in MPOD and a similar average increase (20%) in temporal
processing speed. The intervention resulted in a larger change
than one might predict based on the relatively moderate (butther in an active treatment group (N = 54) or the placebo group (N = 15).
Final Change t-Value p-Valuea
0.25 ± 0.14 +0.08 5.53 <0.003
0.32 ± 0.19 0.00 0.34 2.22
1.37 ± 0.16 +0.13 6.44 <0.003
1.37 ± 0.10 +0.03 0.80 1.32
1.27 ± 0.13 +0.09 4.71 <0.003
1.27 ± 0.10 +0.02 0.37 2.16
0.44 ± 0.15 +0.05 2.89 0.02
0.45 ± 0.21 +0.05 1.45 0.51
1.19 ± 0.13 +0.09 6.48 <0.003
1.20 ± 0.11 +0.06 1.88 0.24
1.09 ± 0.11 +0.10 5.41 <0.003
1.11 ± 0.11 +0.05 1.35 0.60
different active treatment groups.
Final Change t-Value p-Valueb
0.25 ± 0.17 +0.07 3.51 0.006
0.24 ± 0.10 +0.07 4.61 <0.003
1.42 ± 0.17 +0.17 6.27 <0.003
1.30 ± 0.11 +0.06 3.09 0.02
1.29 ± 0.15 +0.10 3.12 0.01
1.24 ± 0.09 +0.07 4.52 <0.003
0.43 ± 0.15 +0.03 0.96 1.05
0.46 ± 0.15 +0.08 3.35 0.009
1.19 ± 0.15 +0.11 5.24 <0.003
1.19 ± 0.10 +0.07 3.90 0.003
1.09 ± 0.13 +0.10 4.78 <0.003
1.09 ± 0.09 +0.10 3.17 0.01
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about 10% of the variance.
These empirical data are consistent with the idea that increas-
ing central levels of xanthophyllic carotenoids can have a generally
positive effect upon brain function. We deﬁne this as salubrious
based on the observation that aging [26] and degenerative disease
(e.g., Alzheimer’s; [7]; minimal hepatic encephalopathy; [25]; Mul-
tiple Sclerosis; [8]) tend to disproportionately affect (i.e., slow)
temporal processing. Faster visual processing tends to be positively
correlated with, for example, improved sports performance [12]
and driver safety [20], reading speed [14], and executive cognitive
function [1].
At this stage, there is not enough information to productively
speculate on precisely how L and Z might inﬂuence processing
speed. A few observations, however, are worth noting. The ﬁrst is
that we found signiﬁcant improvements in the parafovea (see
Tables 3 and 4), where MP density is minimal, further suggesting
that the locus of the effect is, at least in part, the brain itself. Fur-
ther, given the time course that is typically seen (e.g., on how long
it takes to increase MPOD) it is unlikely that L and Z act as nervous
system stimulants like caffeine (stimulants tend to increase visual
processing speeds quickly and relatively transiently; [28]).
Although it is possible that the pigments are acting to create struc-
tural change (e.g., enhancing gap junction communication) within
or across neurons or glia, and this would lead to a more lasting
improvement in processing speed, it is not clear whether the
amounts within brain tissue are sufﬁcient for this purpose (L and
Z in brain is expressed in picomolar amounts as opposed to retina
which is nanomolar; [29]). Direct effects on DNA could amplify the
effects of dietary L and Z on brain and there is some evidence that L
and Z may have such capabilities [27,3,17]. In any event, we do
know that L and Z are in brain and their presence appears to be
more the result of active as opposed to passive mechanisms (since
amounts are in excess of what one would predict based on dietary
intake; [16]). These observations, combined with the empirical
results, implies that L and Z can directly alter brain function, likely
throughout the lifespan.
More generally, these data ﬁt in with a widening body of liter-
ature that has linked diet to central nervous system function even
in young subjects. It can be generally remarked that improving diet
is not simply to prevent acquired or deﬁciency disease, but rather
to optimize function throughout life.Acknowledgment
This study was funded by ZeaVision, LLC.References
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